Search results for "Hematologia"

showing 2 items of 2 documents

Applying extracellular vesicles based therapeutics in clinical trials - an ISEV position paper.

2015

Extracellular vesicles (EVs), such as exosomes and microvesicles, are released by different cell types and participate in physiological and pathophysiological processes. EVs mediate intercellular communication as cell-derived extracellular signalling organelles that transmit specific information from their cell of origin to their target cells. As a result of these properties, EVs of defined cell types may serve as novel tools for various therapeutic approaches, including (a) anti-tumour therapy, (b) pathogen vaccination, (c) immune-modulatory and regenerative therapies and (d) drug delivery. The translation of EVs into clinical therapies requires the categorization of EV-based therapeutics …

Bioquímica clínicaMedizinISCHEMIA-REPERFUSION INJURYBioinformaticsimmunology; neurobiology; haematology; stem cells; tissue regeneration; tumour vaccination; regulationimmunology0302 clinical medicineClinical trialsClinical investigationVERSUS-HOST-DISEASEMedicine and Health SciencesFIELD-FLOW FRACTIONATIONMedicineImmunologiahaematology; immunology; neurobiology; regulation; stem cells; tissue regeneration; tumour vaccinationmedia_common0303 health scienceslcsh:CytologyOUTER-MEMBRANE VESICLESneurobiologyregulationHematologyBiologia experimental3. Good healthTUMOR-DERIVED EXOSOMES030220 oncology & carcinogenesistumour vaccinationDrug deliveryhaematologyPosition PaperCèl·lules mareNeurobiologiaHistologyMedicina InvestigacióCèl·lulesNANOPARTICLE TRACKING ANALYSIStissue regenerationExtracellular vesiclesMESENCHYMAL STEM-CELLS03 medical and health sciencesstem cellsJournal Articlemedia_common.cataloged_instanceREGULATORY T-CELLSEuropean unionlcsh:QH573-671ENDOTHELIAL PROGENITOR CELLSHematologia030304 developmental biologybusiness.industryCell BiologyMicrovesiclesClinical trialPosition paperPharmaceutical manufacturingUMBILICAL-CORD BLOODbusinessNeuroscienceAssaigs clínics
researchProduct

One-year breakthrough SARS-CoV-2 infection and correlates of protection in fully vaccinated hematological patients

2023

AbstractThe long-term clinical efficacy of SARS-CoV-2 vaccines according to antibody response in immunosuppressed patients such as hematological patients has been little explored. A prospective multicenter registry-based cohort study conducted from December 2020 to July 2022 by the Spanish Transplant and Cell Therapy group, was used to analyze the relationship of antibody response over time after full vaccination (at 3–6 weeks, 3, 6 and 12 months) (2 doses) and of booster doses with breakthrough SARS-CoV-2 infection in 1551 patients with hematological disorders. At a median follow-up of 388 days after complete immunization, 266 out of 1551 (17%) developed breakthrough SARS-CoV-2 infection a…

OncologySARS-CoV-2VaccinationCOVID-19Malalties transmissiblesVacunacióHematologyHematologia
researchProduct